Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) saw unusually-high trading volume on Wednesday . Approximately 12,371,974 shares traded hands during trading, an increase of 440% from the previous session’s volume of 2,290,310 shares.The stock last traded at $46.73 and had previously closed at $41.08.

SRPT has been the topic of a number of recent research reports. Barclays PLC initiated coverage on shares of Sarepta Therapeutics in a research note on Wednesday. They set an “equal weight” rating and a $46.00 price objective on the stock. William Blair reiterated an “outperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, July 27th. BidaskClub downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Robert W. Baird reiterated an “outperform” rating and set a $101.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday. Finally, Credit Suisse Group increased their price objective on shares of Sarepta Therapeutics from $5.65 to $81.00 and gave the company an “outperform” rating in a research note on Thursday. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $62.31.

The stock’s market cap is $2.92 billion. The company’s 50 day moving average is $39.28 and its 200-day moving average is $34.10.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million during the quarter, compared to analysts’ expectations of $22.52 million. During the same quarter last year, the company earned ($1.19) EPS. The firm’s revenue for the quarter was up 350000.0% compared to the same quarter last year. Equities research analysts expect that Sarepta Therapeutics, Inc. will post ($1.17) EPS for the current year.

In other news, CEO Douglas S. Ingram acquired 47,058 shares of the business’s stock in a transaction on Thursday, July 27th. The stock was bought at an average price of $42.50 per share, for a total transaction of $1,999,965.00. Following the transaction, the chief executive officer now owns 382,058 shares in the company, valued at $16,237,465. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Shamim Ruff sold 12,138 shares of the company’s stock in a transaction on Friday, July 21st. The stock was sold at an average price of $42.97, for a total transaction of $521,569.86. Following the transaction, the senior vice president now owns 27,312 shares of the company’s stock, valued at approximately $1,173,596.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 78,056 shares of company stock valued at $3,224,208. 9.60% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in the business. Asymmetry Capital Management L.P. raised its position in Sarepta Therapeutics by 82.2% during the 2nd quarter. Asymmetry Capital Management L.P. now owns 158,810 shares of the biotechnology company’s stock worth $5,353,000 after buying an additional 71,630 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in Sarepta Therapeutics by 6.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after buying an additional 271 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its position in Sarepta Therapeutics by 85.8% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 20,871 shares of the biotechnology company’s stock worth $704,000 after buying an additional 9,635 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Sarepta Therapeutics by 3.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 40,188 shares of the biotechnology company’s stock worth $1,355,000 after buying an additional 1,435 shares during the last quarter. Finally, Osterweis Capital Management Inc. purchased a new position in Sarepta Therapeutics during the 2nd quarter worth $3,806,000. Institutional investors own 65.43% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/09/08/sarepta-therapeutics-inc-srpt-sees-large-volume-increase.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.